In The News

In Law360, Margaux Hall Examines Drug Commercialization and Market Access Strategies in Light of Drug Pricing Regulatory Uncertainty Under the Biden Administration

Practices: Health Care, Life Sciences, Drug Pricing & Price Reporting, Health Care Finance & Restructuring, Medicare, Medicaid & Third-Party Reimbursement

In a Law360 article, health care partner Margaux Hall (Washington, D.C.) examines how biopharmaceutical manufacturers and investors should approach commercialization of emerging therapies in light of legal and regulatory uncertainty as the Biden administration rolls out its agenda for biopharmaceutical innovation and drug pricing.  

Margaux analyzes three key drug pricing and market access questions to consider when planning for the launch of a therapy.

Cookie Settings